Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.

Learn More

From Promise to Therapy

Seattle Genetics is conducting clinical trials in these and other therapeutic areas:

  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma
  • Urothelial cancer
  • Breast cancer

View all clinical trials

Join The Seattle Genetics Team

We are a group of passionate innovators dedicated to positively impacting the lives of those living with cancer, and we're always looking to add to our team.

Learn More

Recent News

Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma More

Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting More

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma More

View All News

Seattle Genetics At A Glance

Year founded 1998

Global Headquarters Bothell, WA

Nasdaq SGEN

Number of Employees 1,000+

Clinical & preclinical pipeline programs 12+

ADCs in clinical trials using our technology 20+